Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.

Article  PubMed  CAS  Google Scholar 

Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392:123–33.

Article  PubMed  CAS  Google Scholar 

Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017;35:446–64.

Article  PubMed  CAS  Google Scholar 

Kulangara K, Zhang N, Corigliano E, Guerrero L, Waldroup S, Jaiswal D, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med. 2019;143:330–7.

Article  PubMed  CAS  Google Scholar 

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27–40.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rüschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010;457:299–307.

Article  PubMed  PubMed Central  Google Scholar 

Fox SB, Kumarasinghe MP, Armes JE, Bilous M, Cummings MC, Farshid G, et al. Gastric HER2 testing study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia. Am J Surg Pathol. 2012;36:577–82.

Article  PubMed  Google Scholar 

Robert ME, Rüschoff J, Jasani B, Graham RP, Badve SS, Rodriguez-Justo M, et al. High interobserver variability among pathologists using combined positive score to evaluate PD-L1 expression in gastric, gastroesophageal junction, and esophageal adenocarcinoma. Mod Pathol. 2023;36: 100154.

Article  PubMed  Google Scholar 

Sheffield BS, Garratt J, Kalloger SE, Li-Chang HH, Torlakovic EE, Gilks CB, et al. HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation. Arch Pathol Lab Med. 2014;138:1495–502.

Article  PubMed  Google Scholar 

Hatanaka Y, Kuwata T, Morii E, Kanai Y, Ichikawa H, Kubo T, et al. The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine. Pathol Int. 2021;71:725–40.

Article  PubMed  PubMed Central  Google Scholar 

Nakayama I, Takahari D, Chin K, Wakatsuki T, Takamatsu M, Yamamoto N, et al. Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma. ESMO Open. 2023;8: 101582.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Oono Y, Kuwata T, Takashima K, Yoda Y, Ikematsu H, Shitara K, et al. Clinicopathological features and endoscopic findings of HER2-positive gastric cancer. Surg Endosc. 2018;32:3964–71.

Article  PubMed  Google Scholar 

Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012;23:2656–62.

Article  PubMed  CAS  Google Scholar 

Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1181–95.

Article  PubMed  CAS  Google Scholar 

Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603:942–8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Moehler M, Dvorkin M, Boku N, Özgüroǧlu M, Ryu MH, Muntean AS, et al. Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN gastric 100. J Clin Oncol. 2021;39:966–77.

Article  PubMed  CAS  Google Scholar 

Choritz H, Büsche G, Kreipe H. Quality assessment of HER2 testing by monitoring of positivity rates. Virchows Arch. 2011;459:283–9.

Article  PubMed  PubMed Central  Google Scholar 

Angerilli V, Parente P, Campora M, Ugolini C, Battista S, Cassoni P, et al. HER2-low in gastro-oesophageal adenocarcinoma: a real-world pathological perspective. J Clin Pathol. 2023;76:815–21.

Article  PubMed  CAS  Google Scholar 

Azuma M, Yamashita K, Ishida K, Matsubara M, Hayashi Y, Sakane J, et al. Survey on actual condition of the fixation procedure for histopathological specimens in Japan: Report on the quality control survey questionnaire of the Japanese Association of Medical Technologists. Jpn J Med Technol. 2020;69:660–70.

Google Scholar 

Yanagimoto Y, Imamura H, Adachi S, Odagiri K, Kawase T, Yamashita M, et al. The effect of specimen processing time on HER2 expression in gastric cancer and esophagogastric junction cancer: a single-center retrospective observational study. BMC Cancer. 2023;23:645.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Nakamura M, Watanabe A, Yoshizawa A, Iwasaki S, Nomura A, Matsumura M, et al. The risk of weekend biopsy: Impact of specimen source and fixation status on HER2 assessment in the treatment of advanced gastric cancer (The HER_WEEKEND study). Pathol Int. 2023;73:509–19.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kushima R, Kuwata T, Yao T, Kuriki H, Hashizume K, Masuda S, et al. Interpretation of HER2 tests in gastric cancer: confirmation of interobserver differences and validation of a QA/QC educational program. Virchows Arch. 2014;464:539–45.

Article  PubMed  CAS  Google Scholar 

Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9–20.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O’Shaughnessy JA, et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. 2024. https://doi.org/10.1056/NEJMoa2407086. (online ahead of print).

Article  PubMed  Google Scholar 

Yamaguchi K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in anti-human epidermal growth factor receptor 2 treatment-naive patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort results in a phase II trial. J Clin Oncol. 2023;41:816–25.

Article  PubMed  CAS  Google Scholar